The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).
about
The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The validity of biomarkers as ...... l of Evidence Scheme (QSVLES).
@en
The validity of biomarkers as ...... ation Level of Evidence Scheme
@nl
type
label
The validity of biomarkers as ...... l of Evidence Scheme (QSVLES).
@en
The validity of biomarkers as ...... ation Level of Evidence Scheme
@nl
prefLabel
The validity of biomarkers as ...... l of Evidence Scheme (QSVLES).
@en
The validity of biomarkers as ...... ation Level of Evidence Scheme
@nl
P2093
P2860
P1476
The validity of biomarkers as ...... l of Evidence Scheme (QSVLES).
@en
P2093
Elferink AJ
Gispen-de Wied CC
Kritsidima M
P2860
P2888
P304
P356
10.1007/S12603-009-0049-2
P577
2009-04-01T00:00:00Z